Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Depot medroxyprogesterone and bone mineral density.

P J Ryan1, S P Singh, J Guillebaud

  • 1Department of Nuclear Medicine, Medway Hospital, Gillingham, Kent, UK.

The Journal of Family Planning and Reproductive Health Care
|November 2, 2005
PubMed
Summary

Depot medroxyprogesterone (DMPA) use for over two years is linked to reduced bone mineral density. Women using DMPA, especially those with osteoporosis risk factors, should be monitored for low bone mass.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Echocardiography in Training in Intensive Care - What Have We Learned.

Irish medical journal·2024
Same author

Overview of the Langmuir probe system on the Mega Ampere Spherical Tokamak (MAST) Upgrade.

The Review of scientific instruments·2023
Same author

Controlling spin current polarization through non-collinear antiferromagnetism.

Nature communications·2020
Same author

Magnetism in iridate heterostructures leveraged by structural distortions.

Scientific reports·2019
Same author

Isostructural metal-insulator transition in VO<sub>2</sub>.

Science (New York, N.Y.)·2018
Same author

Ferromagnetism and Charge Order from a Frozen Electron Configuration in Strained Epitaxial LaCoO_{3}.

Physical review letters·2018

Area of Science:

  • Endocrinology
  • Bone Metabolism
  • Pharmacology

Background:

  • Depot medroxyprogesterone acetate (DMPA) is a widely used contraceptive.
  • Concerns exist regarding its potential impact on bone mineral density (BMD).

Purpose of the Study:

  • To evaluate bone loss associated with long-term DMPA use in a general practice setting.
  • To identify potential risk factors for reduced BMD in DMPA users.

Main Methods:

  • Study included 48 women using DMPA for over 2 years.
  • Bone mineral densitometry (BMD) was performed using DEXA at the lumbar spine and femoral neck.
  • Serum estradiol levels were measured.

Main Results:

  • Significantly reduced bone mass was observed at both the lumbar spine and femoral neck.

Related Experiment Videos

  • Over half of the women assessed (56%) exhibited osteopenia or osteoporosis at the lumbar spine.
  • Trends suggested associations between DMPA use, reduced BMD, and risk factors like smoking and family history.

    • Conclusions:

    • Prolonged DMPA usage is associated with low bone mass.
    • Patients using DMPA, particularly those with osteoporosis risk factors, require careful monitoring for bone density loss.